Monoclonal antibodies for the treatment of osteoarthritis.

作者: Shuang Zheng , David J. Hunter , Jianhua Xu , Changhai Ding

DOI: 10.1080/14712598.2016.1229774

关键词: MedicineInflammationJoint diseaseADAMTSBioinformaticsOsteoarthritisPathologicalCochrane LibraryGrowth factorImmunologyMonoclonal antibody

摘要: ABSTRACTIntroduction: Osteoarthritis (OA) is a multifactorial chronic joint disease, and so far, there are no approved disease-modifying anti-OA drugs (DMOADs). There an urgent need to develop therapies for different phenotypes of OA. Monoclonal antibodies (mAb) may slow structural progression, control inflammation relieve pain, thus have the potential be DMOADs.Areas covered: In this review, authors searched literature on PubMed, EMBASE Cochrane Library using keywords, including mAbs, biological agents, OA osteoarthritis, electronically up May 2016. They also included abstracts international conferences. Furthermore, they reviewed experimental clinical studies various mAbs targeting pathological mechanisms OA, ADAMTS, Interleukine-1, tumour necrosis factor, never growth factor vascular endothelial factor.Expert opinion: MAbs treatment under intense investigation results some (e.g., anti-ner...

参考文章(73)
Christine Laine, In the clinic. Osteoarthritis. Annals of Internal Medicine. ,vol. 147, pp. 8- ,(2007) , 10.7326/0003-4819-147-3-200708070-01008
HENRY J. MANKIN, HOWARD DORFMAN, LOUIS LIPPIELLO, ANTRA ZARINS, Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. Journal of Bone and Joint Surgery, American Volume. ,vol. 53, pp. 523- 537 ,(1971) , 10.2106/00004623-197153030-00009
DAVID T. FELSON, Epidemiology of hip and knee osteoarthritis. Epidemiologic Reviews. ,vol. 10, pp. 1- 28 ,(1988) , 10.1093/OXFORDJOURNALS.EPIREV.A036019
L. Rovati, R. Montanelli, R. Caporali, F. Salaffi, B. Canesi, Giani Leardini, Direct and indirect costs of osteoarthritis of the knee. Clinical and Experimental Rheumatology. ,vol. 22, pp. 699- 706 ,(2004)
Mark T. Brown, Frederick T. Murphy, David M. Radin, Isabelle Davignon, Michael D. Smith, Christine R. West, Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis & Rheumatism. ,vol. 65, pp. 1795- 1803 ,(2013) , 10.1002/ART.37950
Susan E Lacy, Chengbin Wu, Dominic J Ambrosi, Chung-Ming Hsieh, Sahana Bose, Renee Miller, Donna M Conlon, Edit Tarcsa, Ravi Chari, Tariq Ghayur, Rajesh V Kamath, Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. mAbs. ,vol. 7, pp. 605- 619 ,(2015) , 10.1080/19420862.2015.1026501
Jason M. Gow, Wayne H. Tsuji, Gary J. Williams, Daniel Mytych, David Sciberras, Shawn L. Searle, Tim Mant, John P. Gibbs, Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects Arthritis Research & Therapy. ,vol. 17, pp. 282- 282 ,(2015) , 10.1186/S13075-015-0797-9
Philippe Goupille, Xavier Chevalier, Bruno Giraudeau, Thierry Conrozier, Jocelyne Marliere, Philippe Kiefer, Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. The Journal of Rheumatology. ,vol. 32, pp. 1317- 1323 ,(2005)
Kang Wang, Jianhua Xu, David J Hunter, Changhai Ding, Investigational drugs for the treatment of osteoarthritis. Expert Opinion on Investigational Drugs. ,vol. 24, pp. 1539- 1556 ,(2015) , 10.1517/13543784.2015.1091880
C.H. Ma, Q. Lv, Y.X. Yu, Y. Zhang, D. Kong, K.R. Niu, C.Q. Yi, Protective effects of tumor necrosis factor-α blockade by adalimumab on articular cartilage and subchondral bone in a rat model of osteoarthritis Brazilian Journal of Medical and Biological Research. ,vol. 48, pp. 863- 870 ,(2015) , 10.1590/1414-431X20154407